| Description | 10-Deazaaminopterin is a poly-gamma-glutamyl metabolite of the experimental anticancer drug, a folic acid antagonist, antineoplastic agent enzyme inhibitor. |
| Synonyms | NSC 311469, NSC-311469, 10-Deaza-aminopterin, NSC311469 |
| molecular weight | 439.42 |
| Molecular formula | C20H21N7O5 |
| CAS | 52454-37-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Marchi E, O'Connor OA. Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Ther Adv Hematol. 2012 Aug;3(4):227-35. doi: 10.1177/2040620712445330. PubMed PMID: 23606933; PubMed Central PMCID: PMC3627334. 2. Zain J, O'Connor O. Pralatrexate: basic understanding and clinical development. Expert Opin Pharmacother. 2010 Jul;11(10):1705-14. doi: 10.1517/14656566.2010.489552. Review. PubMed PMID: 20509772. 3. Marchi E, Paoluzzi L, Scotto L, Seshan VE, Zain JM, Zinzani PL, O'Connor OA. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res. 2010 Jul 15;16(14):3648-58. doi: 10.1158/1078-0432.CCR-10-0671. Epub 2010 May 25. PubMed PMID: 20501616. 4. Zain JM, Marchi E. Pralatrexate - from bench to bedside. Drugs Today (Barc). 2010 Feb;46(2):91-9. doi: 10.1358/dot.2010.46.2.1439260. PubMed PMID: 20393637. |